



# GLYCOPHARM

**The Sugar Code: from bio(chemical) concept to clinics**  
Marie Curie Initial Training Network



## GLYCOPHARM OVERVIEW

Coding of bioinformation in glycans and information transfer via lectins, i.e. the Sugar Code, is key to a wealth of medically relevant processes, as for example infection, immune regulation and malignancy, now awaiting its full exploitation pharmaceutically.

**GLYCOPHARM** is a Marie Curie Initial Training Network devised to offer training to young researchers in the interdisciplinary field of glycosciences. The network is composed of fourteen research groups specialised in chemistry, bioinformatics, biophysics, structural biology, molecular and cell biology, biomedicine and biotechnology, including private companies devoted to the development and commercialisation of innovative procedures in the field of molecular diagnostics.

## GLYCOPHARM OBJECTIVES

**GLYCOPHARM** aims to provide international, intersectoral and multidisciplinary training in an extensive range of skills critical for the drug design and development process, covering the way from bioinformatics to biomedicine. The overall goal of the training programme is to provide young researchers with broad scientific, entrepreneurial and transferable competences for optimizing their career perspectives.

The research programme is aimed at the development of innovative therapeutic agents and strategies, new diagnostic/prognostic tests and new methodologies, e.g., for drug screening. **GLYCOPHARM** focuses on a family of endogenous lectins, the galectins, which play key roles in many clinically relevant processes, including cancer and the immune and inflammatory processes.

## GLYCOPHARM IMPACT

**GLYCOPHARM** will contribute to the development of a new generation of researchers, shaped according to modern society needs and able to associate research competences with the skills required for exploitation of their expertise in both academia and industry.

**GLYCOPHARM** will serve as prototype project to foster the innovative field of glycopharmacy, bringing together public and private sectors on a Europe-wide level.

**GLYCOPHARM** will facilitate the development of pioneering strategies for fighting common diseases, with main focus on cancer.



# GLYCOPHARM PARTNERS



**Agencia Estatal Consejo Superior de Investigaciones Científicas – Spain**  
Instituto de Química-Física Rocasolano  
Centro de Investigaciones Biológicas



**Fundación Universitaria San Pablo CEU – Spain**  
Faculty of Pharmacy, Department of Chemistry



**University College Dublin, National University of Ireland – Ireland**  
School of Chemistry and Chemical Biology



**Ludwig-Maximilians Universität Muenchen – Germany**  
Institut für Physiologie, Physiologische Chemie und Tierernährung



**Universidade do Minho – Portugal**  
CBMA Centro de Biologia Molecular e Ambiental



**Univerzita Karlova V Praze – Czech Republic**  
Anatomický ústav



**Universitätsklinikum Heidelberg – Germany**  
Department of Applied Tumour Biology



**IsoSep AB – Sweden**



**Institute of Applied Biotechnologies a.s. Czech Republic**



**Toscana Biomarkers Srl – Italy**



**Roche Diagnostics GMBH – Germany**



Associated Partner  
**Hokkaido University – Japan**  
Graduate School of Life Science



## CONTACT

### **Project Coordinator**

Dr. Dolores Solís

[d.solis@iqfr.csic.es](mailto:d.solis@iqfr.csic.es)

### **Project Manager**

Dr. Begoña Morales

[bmorales@iqfr.csic.es](mailto:bmorales@iqfr.csic.es)

### **Instituto de Química-Física Rocasolano, CSIC**

Serrano 119, 28006 Madrid, Spain

Tel: +34 91 561 9400

[www.glycopharm.eu](http://www.glycopharm.eu)

## GLYCOPHARM

**Marie Curie Initial Training Network**

PITN-GA-2012-317297

EU Contribution: 3,005,458.30 €

Duration: November 1st 2012 - October 31st 2016

**Disclaimer notice:** The European Commission is neither responsible nor liable for any written content in this flyer.